{"success":true,"data":{"pressRelease":{"id":"97329","rtpr_id":"nACS3BWhSa","ticker":"EXOZ","exchange":"NASDAQ","all_tickers":["EXOZ"],"title":"eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing","author":"ACCESSWIRE","published_at":"2026-07-23T20:15:01.847Z","article_body":"*\nCompany to collaborate with Lawrence Berkeley National Laboratory on\nAI-enabled digital twins designed to accelerate optimization of enzyme-driven\nmanufacturing processes.\n*\nThe 9-month project awarded approximately $747,000 in total funding, including\n$147,000 awarded to eXoZymes\n*\nExpands eXoZymes' AI strategy beyond enzyme engineering into AI-guided\nmanufacturing, leveraging digital twins to predict, optimize and accelerate\ndevelopment of cell-free bioprocesses.\n*\nProvides access to the DOE Genesis Mission Platform, including advanced AI\nmodels, AI agents and high-performance computing infrastructure to accelerate\nfuture platform development.\n\nLOS ANGELES, CA / ACCESS Newswire (https://www.accessnewswire.com/) / July 23,\n2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) (\"eXoZymes\") - a pioneer of\nAI-enhanced enzymes that transform abundant feedstock into valuable\nnutraceuticals and novel medicines, - announced it has been selected to\nparticipate in the inaugural U.S. Department of Energy (DOE) Genesis Mission\n(https://pr.report/o31f), a nationwide initiative bringing together leading\nresearchers, national laboratories and industry leaders to accelerate\nscientific discovery through artificial intelligence.\n\nAs part of the nine-month project, eXoZymes will collaborate with Lawrence\nBerkeley National Laboratory (LBNL) (https://pr.report/o31g) researchers Dr.\nEdward Baidoo (https://pr.report/o31h) and Dr. Hector Garcia Martin\n(https://pr.report/o31i) to develop AI-powered digital twins for cell-free\nbiomanufacturing. The award also provides access to the Genesis Mission\nPlatform, including advanced AI models, AI agents, and high-performance\ncomputing resources.\n\nCEO of eXoZymes, Michael Heltzen, states: \"For centuries, biology has largely\nbeen an observational science. We believe the next generation of\nbiomanufacturing will be built at the intersection of artificial intelligence\nand digital insights into biology. To make that happen, we are accelerating\nthe design-build-test-learn cycle of biomanufacturing development using our\ncell-free platform.\"\n\nHeltzen continues, \"In my opinion, digital biology - including digital twins -\nhas the potential to become one of the defining technologies of this century,\nand projects like the Genesis Mission help accelerate that transition. Digital\ntwins have already transformed industries by allowing engineers to simulate,\noptimize, and refine complex systems, like airplanes in the aviation industry,\nbefore building them in the real world. We believe the same transformation is\ncoming of age in biology, where AI-powered digital twins could fundamentally\nchange how biological manufacturing processes are designed, optimized, and\nscaled.\"\n\nUnder the project, eXoZymes will generate curated experimental datasets from\nmultiple cell-free enzymatic pathways, while Dr. Edward Baidoo's team will\nestablish advanced metabolomic workflows that transform those experiments into\nAI-ready datasets. Dr. Hector Garcia Martin's team will then integrate those\ndatasets into hybrid digital twin models that combine enzyme kinetics, reactor\nphysics and machine learning, creating predictive models capable of\nidentifying optimal operating conditions before laboratory validation.\n\n\"Our cell-free platform generates exceptionally clean, quantitative datasets\nbecause it eliminates many of the biological variables inherent in living-cell\nsystems,\" said Dr. Paul Opgenorth, co-founder and VP of Development at\neXoZymes, who also is the Principal Investigator for the project. \"That makes\nit an ideal foundation for training predictive AI models and building digital\ntwins capable of optimizing increasingly complex biochemical manufacturing\nprocesses.\"\n\nThe Genesis Mission generated the largest response to a funding opportunity in\nDOE history, with 278 projects selected across national laboratories,\nuniversities, companies, and nonprofit organizations. Selected research teams\nreceive access to the Genesis Mission Platform, including advanced AI models,\nAI agent frameworks, and high-performance computing resources to accelerate\nscientific discovery.\n\nAbout eXoZymes\nFounded in 2019, eXoZymes is pioneering a cell-free biomanufacturing platform\nthat uses AI-enhanced enzymes - called exozymes - to make valuable natural\nproducts and new analogs outside living cells. The company's platform is\ndesigned to replace inefficient extraction and petrochemical processes with a\nscalable way to produce high-value molecules for nutraceutical and\npharmaceutical markets.\n\neXoZymes is building a portfolio of biosolutions across NCT, cannabinoid\nanalogs, santalene, and other high-value natural product molecules, with\npotential commercialization paths that include partnerships, licensing and\njoint ventures. Learn more at exozymes.com (https://pr.report/o31j)\n\neXoZymes Safe Harbor\nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements, which are based on certain assumptions and describe the company's\nfuture plans, strategies and expectations, can generally be identified by the\nuse of forward-looking terms such as \"believe,\" \"expect,\" \"may,\" \"will,\"\n\"should,\" \"would,\" \"could,\" \"seek,\" \"intend,\" \"plan,\" \"goal,\" \"project,\"\n\"estimate,\" \"anticipate,\" \"strategy,\" \"future,\" \"likely,\" \"potential,\" or\nother comparable terms, although not all forward-looking statements contain\nthese identifying words. All statements other than statements of historical\nfacts included in this press release regarding the company's strategies,\nprospects, financial condition, operations, costs, plans and objectives are\nforward-looking statements. Actual results could differ materially for a\nvariety of reasons. You should carefully consider the risks and uncertainties\ndescribed in the \"Risk Factors\" section of eXoZymes' quarterly reports on Form\n10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from\ntime to time by the company with the Securities and Exchange Commission. These\nfilings identify and address important risks and uncertainties that could\ncause actual events and results to differ materially from those contained in\nthe forward-looking statements. Forward-looking statements speak only as of\nthe date they are made. Readers are cautioned not to put undue reliance on\nforward-looking statements, and eXoZymes assumes no obligation and does not\nintend to update or revise these forward-looking statements, whether as a\nresult of new information, future events, or otherwise. eXoZymes does not give\nany assurance that it will achieve its expectations.\n\neXoZymes contact\nLasse Görlitz, VP of Comms & IR\n(858) 319-7135\npress@exozymes.com\nLinkedIn (https://pr.report/o31k) | X (https://pr.report/o31l) | YouTube\n(https://pr.report/o31m)\n\nSOURCE: eXoZymes\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/exozymes-selected-for-does-genesis-mission-to-advance-ai-powered-digital-twins-for-ce-1195498)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS3BWhSa","title":"eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing","author":"ACCESSWIRE","ticker":"EXOZ","created":"2026-07-23T20:15:01.847Z","tickers":["EXOZ"],"exchange":"NASDAQ","article_body":"*\nCompany to collaborate with Lawrence Berkeley National Laboratory on\nAI-enabled digital twins designed to accelerate optimization of enzyme-driven\nmanufacturing processes.\n*\nThe 9-month project awarded approximately $747,000 in total funding, including\n$147,000 awarded to eXoZymes\n*\nExpands eXoZymes' AI strategy beyond enzyme engineering into AI-guided\nmanufacturing, leveraging digital twins to predict, optimize and accelerate\ndevelopment of cell-free bioprocesses.\n*\nProvides access to the DOE Genesis Mission Platform, including advanced AI\nmodels, AI agents and high-performance computing infrastructure to accelerate\nfuture platform development.\n\nLOS ANGELES, CA / ACCESS Newswire (https://www.accessnewswire.com/) / July 23,\n2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) (\"eXoZymes\") - a pioneer of\nAI-enhanced enzymes that transform abundant feedstock into valuable\nnutraceuticals and novel medicines, - announced it has been selected to\nparticipate in the inaugural U.S. Department of Energy (DOE) Genesis Mission\n(https://pr.report/o31f), a nationwide initiative bringing together leading\nresearchers, national laboratories and industry leaders to accelerate\nscientific discovery through artificial intelligence.\n\nAs part of the nine-month project, eXoZymes will collaborate with Lawrence\nBerkeley National Laboratory (LBNL) (https://pr.report/o31g) researchers Dr.\nEdward Baidoo (https://pr.report/o31h) and Dr. Hector Garcia Martin\n(https://pr.report/o31i) to develop AI-powered digital twins for cell-free\nbiomanufacturing. The award also provides access to the Genesis Mission\nPlatform, including advanced AI models, AI agents, and high-performance\ncomputing resources.\n\nCEO of eXoZymes, Michael Heltzen, states: \"For centuries, biology has largely\nbeen an observational science. We believe the next generation of\nbiomanufacturing will be built at the intersection of artificial intelligence\nand digital insights into biology. To make that happen, we are accelerating\nthe design-build-test-learn cycle of biomanufacturing development using our\ncell-free platform.\"\n\nHeltzen continues, \"In my opinion, digital biology - including digital twins -\nhas the potential to become one of the defining technologies of this century,\nand projects like the Genesis Mission help accelerate that transition. Digital\ntwins have already transformed industries by allowing engineers to simulate,\noptimize, and refine complex systems, like airplanes in the aviation industry,\nbefore building them in the real world. We believe the same transformation is\ncoming of age in biology, where AI-powered digital twins could fundamentally\nchange how biological manufacturing processes are designed, optimized, and\nscaled.\"\n\nUnder the project, eXoZymes will generate curated experimental datasets from\nmultiple cell-free enzymatic pathways, while Dr. Edward Baidoo's team will\nestablish advanced metabolomic workflows that transform those experiments into\nAI-ready datasets. Dr. Hector Garcia Martin's team will then integrate those\ndatasets into hybrid digital twin models that combine enzyme kinetics, reactor\nphysics and machine learning, creating predictive models capable of\nidentifying optimal operating conditions before laboratory validation.\n\n\"Our cell-free platform generates exceptionally clean, quantitative datasets\nbecause it eliminates many of the biological variables inherent in living-cell\nsystems,\" said Dr. Paul Opgenorth, co-founder and VP of Development at\neXoZymes, who also is the Principal Investigator for the project. \"That makes\nit an ideal foundation for training predictive AI models and building digital\ntwins capable of optimizing increasingly complex biochemical manufacturing\nprocesses.\"\n\nThe Genesis Mission generated the largest response to a funding opportunity in\nDOE history, with 278 projects selected across national laboratories,\nuniversities, companies, and nonprofit organizations. Selected research teams\nreceive access to the Genesis Mission Platform, including advanced AI models,\nAI agent frameworks, and high-performance computing resources to accelerate\nscientific discovery.\n\nAbout eXoZymes\nFounded in 2019, eXoZymes is pioneering a cell-free biomanufacturing platform\nthat uses AI-enhanced enzymes - called exozymes - to make valuable natural\nproducts and new analogs outside living cells. The company's platform is\ndesigned to replace inefficient extraction and petrochemical processes with a\nscalable way to produce high-value molecules for nutraceutical and\npharmaceutical markets.\n\neXoZymes is building a portfolio of biosolutions across NCT, cannabinoid\nanalogs, santalene, and other high-value natural product molecules, with\npotential commercialization paths that include partnerships, licensing and\njoint ventures. Learn more at exozymes.com (https://pr.report/o31j)\n\neXoZymes Safe Harbor\nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements, which are based on certain assumptions and describe the company's\nfuture plans, strategies and expectations, can generally be identified by the\nuse of forward-looking terms such as \"believe,\" \"expect,\" \"may,\" \"will,\"\n\"should,\" \"would,\" \"could,\" \"seek,\" \"intend,\" \"plan,\" \"goal,\" \"project,\"\n\"estimate,\" \"anticipate,\" \"strategy,\" \"future,\" \"likely,\" \"potential,\" or\nother comparable terms, although not all forward-looking statements contain\nthese identifying words. All statements other than statements of historical\nfacts included in this press release regarding the company's strategies,\nprospects, financial condition, operations, costs, plans and objectives are\nforward-looking statements. Actual results could differ materially for a\nvariety of reasons. You should carefully consider the risks and uncertainties\ndescribed in the \"Risk Factors\" section of eXoZymes' quarterly reports on Form\n10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from\ntime to time by the company with the Securities and Exchange Commission. These\nfilings identify and address important risks and uncertainties that could\ncause actual events and results to differ materially from those contained in\nthe forward-looking statements. Forward-looking statements speak only as of\nthe date they are made. Readers are cautioned not to put undue reliance on\nforward-looking statements, and eXoZymes assumes no obligation and does not\nintend to update or revise these forward-looking statements, whether as a\nresult of new information, future events, or otherwise. eXoZymes does not give\nany assurance that it will achieve its expectations.\n\neXoZymes contact\nLasse Görlitz, VP of Comms & IR\n(858) 319-7135\npress@exozymes.com\nLinkedIn (https://pr.report/o31k) | X (https://pr.report/o31l) | YouTube\n(https://pr.report/o31m)\n\nSOURCE: eXoZymes\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/exozymes-selected-for-does-genesis-mission-to-advance-ai-powered-digital-twins-for-ce-1195498)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-07-23T20:15:03.359137222Z","server_sent_at_ms":1784837703359},"received_at":"2026-07-23T20:15:03.410Z","source_url":"https://www.accessnewswire.com/newsroom/en/biotechnology/exozymes-selected-for-does-genesis-mission-to-advance-ai-powered-digital-twins-for-ce-1195498"},"analysis":{"id":"86370","press_release_id":"97329","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"eXoZymes was selected for the U.S. Department of Energy's Genesis Mission to collaborate on AI-powered digital twins for cell-free biomanufacturing.\n\nThe nine-month project with Lawrence Berkeley National Laboratory includes $147,000 in funding for eXoZymes out of a total $747,000 award.\n\nParticipation grants access to the Genesis Mission Platform, including advanced AI models and high-performance computing infrastructure to accelerate process optimization.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"DOE partnership validates AI strategy but offers minimal immediate financial impact."},"keyFigures":{"customDimensions":{"total_project_funding":747000,"project_duration_months":9,"funding_awarded_to_filer":147000}},"quotedText":"In my opinion, digital biology - including digital twins - has the potential to become one of the defining technologies of this century, and projects like the Genesis Mission help accelerate that transition.","namedEntities":{"people":[{"name":"Michael Heltzen","role":"CEO"},{"name":"Dr. Edward Baidoo","role":"LBNL Researcher"},{"name":"Dr. Hector Garcia Martin","role":"LBNL Researcher"},{"name":"Dr. Paul Opgenorth","role":"Co-founder and VP of Development"},{"name":"Lasse Görlitz","role":"VP of Comms & IR"}],"products":["exozymes","Genesis Mission Platform"],"companies":[{"name":"eXoZymes Inc.","ticker":"EXOZ"},{"name":"U.S. Department of Energy","relationship":"partner"},{"name":"Lawrence Berkeley National Laboratory","relationship":"partner"}],"dollarAmounts":[{"amount":"$747,000","context":"total project funding"},{"amount":"$147,000","context":"funding awarded to eXoZymes"}]},"materialImpact":{"score":2,"reasoning":"Strategic collaboration with the DOE and LBNL validates the company's AI and digital twin strategy, though the direct funding of $147,000 is financially immaterial."},"tickerRelevance":{"others":[],"primary":"EXOZ"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-micro-cap","eventGravity":"grant-partnership","sectorWeight":"biotech"}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"eXoZymes was selected for the U.S. Department of Energy's Genesis Mission to collaborate on AI-powered digital twins for cell-free biomanufacturing.\n\nThe nine-month project with Lawrence Berkeley National Laboratory includes $147,000 in funding for eXoZymes out of a total $747,000 award.\n\nParticipation grants access to the Genesis Mission Platform, including advanced AI models and high-performance computing infrastructure to accelerate process optimization.","key_figures":{"customDimensions":{"total_project_funding":747000,"project_duration_months":9,"funding_awarded_to_filer":147000}},"named_entities":{"people":[{"name":"Michael Heltzen","role":"CEO"},{"name":"Dr. Edward Baidoo","role":"LBNL Researcher"},{"name":"Dr. Hector Garcia Martin","role":"LBNL Researcher"},{"name":"Dr. Paul Opgenorth","role":"Co-founder and VP of Development"},{"name":"Lasse Görlitz","role":"VP of Comms & IR"}],"products":["exozymes","Genesis Mission Platform"],"companies":[{"name":"eXoZymes Inc.","ticker":"EXOZ"},{"name":"U.S. Department of Energy","relationship":"partner"},{"name":"Lawrence Berkeley National Laboratory","relationship":"partner"}],"dollarAmounts":[{"amount":"$747,000","context":"total project funding"},{"amount":"$147,000","context":"funding awarded to eXoZymes"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-23T23:50:39.078Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-micro-cap","eventGravity":"grant-partnership","sectorWeight":"biotech"}},"durationMs":389686,"modelName":"glm-4.7"}}